Under the GSK collaboration, Ambit will employ its proprietary kinase platform to profile kinase target specificity of selected GSK compounds, thereby accelerating the discovery and development of novel
In a study conducted in the department of psychiatry and behavioral sciences at Emory University School of Medicine, researchers observed that patients who develop depressive symptoms during interferon-alpha
Mutations in mitochondrial DNA (mtDNA) are key to the development of prostate cancer, according to research by scientists at Emory University School of Medicine and the University of
Alvesco (Ciclesonide) is a novel inhaled corticosteroid (ICS) for the treatment of adults suffering from persistent asthma. ICSs are considered to be the foundation of asthma treatment and
Menactra vaccine is the first quadrivalent conjugate vaccine licensed in the US for the prevention of meningococcal disease and is designed to offer protection against four serogroups of
Mevacor inhibits an early step in the lead-up to cholesterol, the conversion of HMG-CoA to mevalonate. The Mevacor (lovastatin) proposal, submitted for review by Merck and Johnson and
The molecular target is one of several ion channel targets Icagen has identified for the treatment of pain. The Icagen/Abbott collaboration in pain, which began in 2001, provided
Emergent BioSolutions and the Health Protection Agency (HPA) are both leaders in biodefense vaccines, with long-established capabilities in the prevention of botulism dating back to the 1950s. In
Avastin is now approved for the first-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with the chemotherapy regimens of intravenous 5-fluorouracil/folinic acid
Osmotics Pharma (OPI) has the exclusive worldwide rights covering technologies developed by the University of California and Brigham Young University. Applications of these technologies are currently being tested
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.